Quanterix Corp
Quanterix Corporation (Nasdaq: QTRX) develops and sells life-sciences instruments, consumables and services for sensitive biomarker analysis and spatial biology. Its Simoa technology detects proteins at very low concentrations in blood and other fluids, while its spatial biology platforms measure multiple biomarkers… From the company’s description.
Over the twelve months to Jun 30, 2026, Quanterix Corp reported revenue of $153.41M, up 22.0% from a year earlier, and a net loss of $123.11M. Its operating margin was −99.6%, and operations used $80.92M in cash. In fiscal 2025, it reported revenue of $138.90M, up 1.1% from fiscal 2024, and a net loss of $107.15M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Quanterix Corp does
In the company’s own words
Quanterix Corporation (Nasdaq: QTRX) develops and sells life-sciences instruments, consumables and services for sensitive biomarker analysis and spatial biology. Its Simoa technology detects proteins at very low concentrations in blood and other fluids, while its spatial biology platforms measure multiple biomarkers in intact tissue at single-cell resolution. Customers include research laboratories, contract research organizations, academic institutions and biopharmaceutical companies; healthcare providers also use its clinical laboratory testing services. The company sells Simoa and spatial biology instruments, assay kits, reagents and software, and provides contract research and clinical testing through its CLIA-certified Accelerator Laboratory, including four laboratory-developed tests for neurological conditions. Its principal product lines include HD-X, SR-X and SP-X instruments, and Akoya’s PhenoCycler and PhenoImager platforms and PhenoCode panels. Quanterix acquired Akoya Biosciences in 2025, adding spatial biology solutions, and acquired Emission in 2025, adding magnetic-bead manufacturing and a mid-plex platform. The company reports an installed base of more than 2,500 instruments. Its website is www.quanterix.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- BILLERICA, MA
- Fiscal year end
- December
- CIK
- 1503274
- SIC
- 3826
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Quanterix Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Quanterix Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Quanterix Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Quanterix Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Quanterix Corp's last four quarterly filings that the numbers alone won't show?”